IMMUCOR INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-08-12: Form 8-K; Period of report 2013-08-06; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2013-03-22: Form 8-K; Period of report 2013-03-22; Description 8.01 Other Events; Details 8.01.
- 2013-02-22: Form 8-K; Period of report 2013-02-19; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2013-01-31: Form 8-K; Period of report 2013-01-25; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-08-12 | 8-K | 2013-08-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 6, 2013, the Compensation Committee (the “Committee”) of the Board of Directors of Immucor, Inc. (the “Company”) adopted the Annual Bonus Plan in order to reward officers of the Company for their contribution to the Company’s growth and profitability. | blud20130812_8k.htm |
| 2013-03-22 | 8-K | 2013-03-22 | 8.01 Other Events | 8.01 On March 22, 2013, pursuant to the terms of the Stock Purchase Agreement dated January 3, 2013 by and between Immucor, Inc. (the “Company”) and Gen-Probe Incorporated (“Gen-Probe”), the Company completed its acquisition of the outstanding capital stock of Gen-Probe Holdings, Inc. and Gen-Probe GTI Diagnostics Holding Company from Gen-Probe for a purchase price of $85 million, as adjusted. | blud20130321_8k.htm |
| 2013-02-22 | 8-K | 2013-02-19 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 is incorporated by reference into this Item 2.03. | immucore_8k-021913.htm |
| 2013-01-31 | 8-K | 2013-01-25 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 is incorporated by reference into this Item 2.03. | immucor_8k-012513.htm |
| 2013-01-16 | 8-K | 2013-01-16 | 8.01 Other Events | 8.01 In connection with the Company’s previously announced agreement to acquire the LIFECODES business from Hologic, Inc. (the “Acquisition”) for $85 million in cash, the Company received a debt commitment letter from Citigroup Global Markets Inc., JPMorgan Chase Bank, N.A. and J.P. Morgan Securities LLC that provides an aggregate of $50 million in debt financing (the “Debt Financing”) to the Company. | immucor_8k-011613.htm |
| 2013-01-09 | 8-K | 2013-01-03 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On January 3, 2013, the Company issued a press release announcing the execution of the Stock Purchase Agreement. | immucor_8k-010313.htm |